# | Title | Journal | Year | Citations |
---|
1 | Deconstructing the molecular portraits of breast cancer | Molecular Oncology | 2011 | 1,059 |
2 | MicroRNA and cancer | Molecular Oncology | 2012 | 963 |
3 | Emerging functions of the EGFR in cancer | Molecular Oncology | 2018 | 927 |
4 | The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression | Molecular Oncology | 2007 | 872 |
5 | The role of histone deacetylases (HDACs) in human cancer | Molecular Oncology | 2007 | 796 |
6 | The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings | Molecular Oncology | 2011 | 664 |
7 | Imaging and cancer: A review | Molecular Oncology | 2008 | 613 |
8 | Cancer biomarkers | Molecular Oncology | 2012 | 600 |
9 | Epithelial–mesenchymal transition in tumor metastasis | Molecular Oncology | 2017 | 511 |
10 | Discovery of small molecule cancer drugs: Successes, challenges and opportunities | Molecular Oncology | 2012 | 447 |
11 | Circulating tumor cell technologies | Molecular Oncology | 2016 | 432 |
12 | EMT and inflammation: inseparable actors of cancer progression | Molecular Oncology | 2017 | 426 |
13 | Targeting immunogenic cell death in cancer | Molecular Oncology | 2020 | 383 |
14 | Histone deacetylases and cancer | Molecular Oncology | 2012 | 373 |
15 | Histological types of breast cancer: How special are they? | Molecular Oncology | 2010 | 365 |
16 | Early‐onset colorectal cancer in young individuals | Molecular Oncology | 2019 | 365 |
17 | Tumour heterogeneity and the evolution of polyclonal drug resistance | Molecular Oncology | 2014 | 347 |
18 | New insights into the role of EMT in tumor immune escape | Molecular Oncology | 2017 | 332 |
19 | Exosome‐delivered circRNA promotes glycolysis to induce chemoresistance through the miR‐122‐PKM2 axis in colorectal cancer | Molecular Oncology | 2020 | 327 |
20 | Targeted proteomic strategy for clinical biomarker discovery | Molecular Oncology | 2009 | 321 |
21 | EMT and MET: necessary or permissive for metastasis? | Molecular Oncology | 2017 | 319 |
22 | Frequent expression of PD‐L1 on circulating breast cancer cells | Molecular Oncology | 2015 | 303 |
23 | The circRNA–microRNA code: emerging implications for cancer diagnosis and treatment | Molecular Oncology | 2019 | 300 |
24 | Genetic susceptibility to breast cancer | Molecular Oncology | 2010 | 291 |
25 | The biology of cancer testis antigens: Putative function, regulation and therapeutic potential | Molecular Oncology | 2011 | 281 |
26 | HDAC inhibitor‐based therapies: Can we interpret the code? | Molecular Oncology | 2012 | 271 |
27 | Cell‐to‐cell communication: microRNAs as hormones | Molecular Oncology | 2017 | 267 |
28 | ZKSCAN1 gene and its related circular RNA (circZKSCAN1) both inhibit hepatocellular carcinoma cell growth, migration, and invasion but through different signaling pathways | Molecular Oncology | 2017 | 259 |
29 | Triple‐negative breast cancer: Present challenges and new perspectives | Molecular Oncology | 2010 | 252 |
30 | Circulating tumor DNA as a non‐invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types | Molecular Oncology | 2015 | 248 |
31 | Autophagy induction impairs migration and invasion by reversing EMT in glioblastoma cells | Molecular Oncology | 2015 | 245 |
32 | The epigenetics of breast cancer | Molecular Oncology | 2010 | 242 |
33 | Challenges in circulating tumor cell detection by the CellSearch system | Molecular Oncology | 2016 | 231 |
34 | Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site | Molecular Oncology | 2008 | 228 |
35 | DNA methylation and microRNA dysregulation in cancer | Molecular Oncology | 2012 | 228 |
36 | Biobanking for better healthcare | Molecular Oncology | 2008 | 224 |
37 | Transfection of chimeric anti‐CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells | Molecular Oncology | 2014 | 215 |
38 | Physical activity, obesity and sedentary behavior in cancer etiology: epidemiologic evidence and biologic mechanisms | Molecular Oncology | 2021 | 210 |
39 | Trials with ‘epigenetic’ drugs: An update | Molecular Oncology | 2012 | 208 |
40 | Genetic and epigenetic alterations as biomarkers for cancer detection, diagnosis and prognosis | Molecular Oncology | 2007 | 206 |
41 | EMT: Present and future in clinical oncology | Molecular Oncology | 2017 | 205 |
42 | Exosomal proteins as prognostic biomarkers in non‐small cell lung cancer | Molecular Oncology | 2016 | 202 |
43 | Progression from ductal carcinoma in situ to invasive breast cancer: Revisited | Molecular Oncology | 2013 | 195 |
44 | Multi‐marker analysis of circulating cell‐free DNA toward personalized medicine for colorectal cancer | Molecular Oncology | 2014 | 192 |
45 | Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530 | Molecular Oncology | 2009 | 190 |
46 | Drug resistance to targeted therapies: Déjà vu all over again | Molecular Oncology | 2014 | 187 |
47 | Circulating and disseminated tumor cells: harbingers or initiators of metastasis? | Molecular Oncology | 2017 | 182 |
48 | Determinants of metastatic competency in colorectal cancer | Molecular Oncology | 2017 | 180 |
49 | The Contribution of BRCA1 and BRCA2 to Ovarian Cancer | Molecular Oncology | 2009 | 178 |
50 | Mass spectrometry based biomarker discovery, verification, and validation — Quality assurance and control of protein biomarker assays | Molecular Oncology | 2014 | 178 |